top of page
  • Not yet recruiting

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma

iMMagine-1

CART-ddBCMA-iMMagine-1

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma


A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy.


Sponsor

Arcellx, Inc


Collaborator

Multiple Myeloma Research Foundation

 

ClinicalTrials.gov Identifier: NCT05396885

Official Title: A Phase II Study of CART-ddBMCA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (iMMagine-1)

First Posted: May 31, 2022